Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

28 April 2022

RTW Venture Fund Limited

Quarterly Update

RTW Venture Fund Limited (the "Company") is pleased to announce the Fact Sheet for the quarter ended 31 March 2022 is now available on the Company's website in the Document Library Section www.rtwfunds.com/venture-fund.

For Further Information

RTW Investments, LP +1 (646) 597 6980Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Woody Stileman, Managing Director

Elysium Fund Management Limited +44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds

Jérémie Birnbaum

James Bouverat (Sales)

BofA Securities +44 (0) 20 7628 1000

Edward Peel

Kieran Millar

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund Limited invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.